ELVN · Company research
Enliven Therapeutics, Inc. Common Stock (ELVN): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
17records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| [Form 3] Enliven Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan | [Form 3] Enliven Therapeutics, Inc. Initial Statement of Beneficial Ownership Stock Titan | View source ↗ | Stock Titan | Oct 16, 2026 | neutral | 0 | 0.6 |
| A 23,394-option grant to director Ball at Enliven Therapeutics (ELVN) carries a $39.28 exercise price. - Stock Titan | A 23,394-option grant to director Ball at Enliven Therapeutics (ELVN) carries a $39.28 exercise price. Stock Titan | View source ↗ | Stock Titan | Oct 16, 2026 | neutral | 0 | 0.6 |
| The Technical Signals Behind (ELVN) That Institutions Follow - Stock Traders Daily | The Technical Signals Behind (ELVN) That Institutions Follow Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 11, 2026 | neutral | 0 | 0.6 |
| Why Enliven Therapeutics' (ELVN) ENABLE-2 Trial Design Raises New Questions About Its CML Strategy - Yahoo Finance | Why Enliven Therapeutics' (ELVN) ENABLE-2 Trial Design Raises New Questions About Its CML Strategy Yahoo Finance | View source ↗ | Yahoo Finance | Oct 10, 2026 | neutral | 0 | 0.6 |
| The FDA aligned with Enliven on a leukemia trial design for about 450 adults, with a start planned before year-end. - Stock Titan | The FDA aligned with Enliven on a leukemia trial design for about 450 adults, with a start planned before year-end. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| After exercising options at $15.47, Enliven Therapeutics (ELVN) director sells 13,000 shares. - Stock Titan | After exercising options at $15.47, Enliven Therapeutics (ELVN) director sells 13,000 shares. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| Understanding the Setup: (ELVN) and Scalable Risk - Stock Traders Daily | Understanding the Setup: (ELVN) and Scalable Risk Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 1, 2026 | neutral | 0 | 0.6 |
| $ELVN stock is down 9% today. Here's what we see in our data. - Quiver Quantitative | $ELVN stock is down 9% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 16, 2026 | neutral | 0 | 0.6 |
| Insider Sale: Director at $ELVN Sells 158,795 Shares - Quiver Quantitative | Insider Sale: Director at $ELVN Sells 158,795 Shares Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 7, 2026 | neutral | 0 | 0.6 |
| 5 Biotech Stocks That Delivered Big Gains - Key Catalysts Ahead For QURE, CDNA, ADPT, ELVN & AMLX - RTTNews | 5 Biotech Stocks That Delivered Big Gains - Key Catalysts Ahead For QURE, CDNA, ADPT, ELVN & AMLX RTTNews | View source ↗ | RTTNews | Aug 2, 2026 | neutral | 0 | 0.6 |
| Enliven Therapeutics (ELVN) Stock Looks Overvalued As Returns Surge But Book Value Lags - Yahoo Finance | Enliven Therapeutics (ELVN) Stock Looks Overvalued As Returns Surge But Book Value Lags Yahoo Finance | View source ↗ | Yahoo Finance | Jul 3, 2026 | neutral | 0 | 0.6 |
| Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - PR Newswire | Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares PR Newswire | View source ↗ | PR Newswire | Jun 15, 2026 | neutral | 0 | 0.6 |
| Enliven Therapeutics (ELVN) Soars on Stellar Leukemia Drug Trial - Yahoo Finance | Enliven Therapeutics (ELVN) Soars on Stellar Leukemia Drug Trial Yahoo Finance | View source ↗ | Yahoo Finance | Jun 13, 2026 | neutral | 0 | 0.6 |
| ELVN Stock Jumps As FDA Clears Path For Phase 3 ENABLE Trial - StocksToTrade | ELVN Stock Jumps As FDA Clears Path For Phase 3 ENABLE Trial StocksToTrade | View source ↗ | StocksToTrade | Jun 12, 2026 | neutral | 0 | 0.6 |
| Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - PR Newswire | Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants PR Newswire | View source ↗ | PR Newswire | Jun 11, 2026 | neutral | 0 | 0.6 |
| Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants - PR Newswire | Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants PR Newswire | View source ↗ | PR Newswire | Jun 11, 2026 | neutral | 0 | 0.6 |
| Enliven Therapeutics (ELVN) Soars to 5-Year High as Analysts ‘Upbeat’ - Yahoo Finance | Enliven Therapeutics (ELVN) Soars to 5-Year High as Analysts ‘Upbeat’ Yahoo Finance | View source ↗ | Yahoo Finance | Mar 25, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.